CN113980004B - 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法 - Google Patents
一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法 Download PDFInfo
- Publication number
- CN113980004B CN113980004B CN202111210020.8A CN202111210020A CN113980004B CN 113980004 B CN113980004 B CN 113980004B CN 202111210020 A CN202111210020 A CN 202111210020A CN 113980004 B CN113980004 B CN 113980004B
- Authority
- CN
- China
- Prior art keywords
- compound
- methoxy
- nmr
- ethyl acetate
- dihydrofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims abstract description 36
- 239000000758 substrate Substances 0.000 claims abstract description 18
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims abstract description 10
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000000654 additive Substances 0.000 claims abstract description 10
- 230000000996 additive effect Effects 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000017281 sodium acetate Nutrition 0.000 claims abstract 2
- 239000001632 sodium acetate Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004185 ester group Chemical group 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 150000002475 indoles Chemical class 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- -1 indole compound Chemical class 0.000 abstract description 86
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 9
- 238000007273 lactonization reaction Methods 0.000 abstract description 6
- 230000005012 migration Effects 0.000 abstract description 6
- 238000013508 migration Methods 0.000 abstract description 6
- 238000006772 olefination reaction Methods 0.000 abstract description 6
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 5
- 125000000524 functional group Chemical group 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 238000001308 synthesis method Methods 0.000 abstract description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 abstract 1
- 229910052703 rhodium Inorganic materials 0.000 abstract 1
- 239000010948 rhodium Substances 0.000 abstract 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 282
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- 238000003818 flash chromatography Methods 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 48
- 239000000741 silica gel Substances 0.000 description 48
- 229910002027 silica gel Inorganic materials 0.000 description 48
- 239000007787 solid Substances 0.000 description 44
- 239000003208 petroleum Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical group O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000003321 amplification Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- KHSREFIWULNDAB-YCUBLIQYSA-N Sorgolactone Chemical compound O([C@@H]1C2=C(C[C@@H]11)CCC[C@@H]2C)C(=O)\C1=C\O[C@@H]1OC(=O)C(C)=C1 KHSREFIWULNDAB-YCUBLIQYSA-N 0.000 description 1
- KHSREFIWULNDAB-MRZMDFQOSA-N Sorgolactone Natural products O(/C=C/1\C(=O)O[C@H]2[C@@H]\1CC1=C2[C@@H](C)CCC1)[C@@H]1OC(=O)C(C)=C1 KHSREFIWULNDAB-MRZMDFQOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- WKHWQWGTSSQIRF-UHFFFAOYSA-N lambertellol A Natural products O1C(=O)C(C)=CC11C(O)C2=CC=CC(O)=C2C(=O)C1 WKHWQWGTSSQIRF-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 230000007226 seed germination Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
Abstract
本发明提供了一种具有呋喃‑2(5H)‑酮骨架的化合物及其制备方法，属于有机合成技术领域。本发明采用铑催化C–H烯化/导向基迁移/内酯化串联反应制备一系列具有呋喃‑2(5H)‑酮骨架的化合物，其反应条件为：以吲哚化合物Ⅰ和4‑羟基‑2‑炔酸酯化合物Ⅱ为底物、以[Cp*RhCl2]2为催化剂、醋酸钠为添加剂、1,4‑二氧六环为溶剂，反应得到具有呋喃‑2(5H)‑酮骨架的目标化合物Ⅲ。本发明提供的合成方法具有底物适用范围广、区域选择性和立体选择性高、产率良好、官能团耐受性好、反应步骤经济、反应条件温和等优点。本发明的合成反应涉及的反应方程式如下：
Description
技术领域
本发明属于有机合成技术领域，具体涉及一种具有呋喃-2(5H)- 酮骨架的化合物及其制备方法。
背景技术
研究表明，许多药物和活性天然产物分子均具有呋喃-2(5H)-酮骨架，如下式所示，罗非昔布是一种选择性环氧化酶-2(COX-2)抑制剂，用于治疗骨性关节炎和类风湿性关节炎，也用于缓解急性疼痛和治疗原发性痛经。天然产物Sorgolactone具有促进种子发芽活性，天然产物LambertellolA具有抗菌活性，天然产物KallolideA具有抗炎活性。由此可见，具有呋喃-2(5H)-酮结构的化合物具有潜在的药理应用价值。因此，发展一种高效的制备方法来合成呋喃-2(5H)-酮类化合物具有重要的理论价值和应用价值。
发明内容
本发明目的在于提供一种具有呋喃-2(5H)-酮骨架的化合物及其制备方法。本发明提供的制备方法具有底物适用范围广、区域选择性和立体选择性高、产率良好、官能团耐受性好、反应步骤经济、反应条件温和等优点。
本发明的目的之一是提供一种具有呋喃-2(5H)-酮骨架的化合物的制备方法，所述具有呋喃-2(5H)-酮骨架的化合物结构式如式<Ⅲ> 所示，所述制备方法包括如下步骤：以式<Ⅰ>所示吲哚化合物和式< Ⅱ>所示4-羟基-2-炔酸酯化合物为底物，并以[Cp*RhCl2]2为催化剂、 NaOAc为添加剂、1,4-二氧六环为溶剂，反应得到式<Ⅲ>所示化合物；
上述方法所涉及的反应式如下：
其中，R1代表苯环上任意位置的取代基，其选自以下基团：氢、卤素、烷基、烷氧基、3-6元含一个N、O或S原子的杂环、氰基、酯基；
R2选自以下基团：氢、取代或未取代的烷基；
R3选自以下基团：取代或未取代烷基；
R4和R5各自独立地选自以下基团：氢、取代或未取代烷基、芳基、环烷基；
R6选自烷基；
所述的取代指基团上的一个或多个氢原子被选自下组的任意基团取代：苯基、酯基。
进一步的是，所述的卤素包括F、Cl、Br或I。
进一步的是，所述的烷基包括甲基、乙基、异丙基、正丁基、叔丁基或正戊基；所述的烷氧基包括甲氧基或乙氧基；所述的取代烷基包括苄基或CH2CO2Et；所述的芳基包括苯基、对甲基取代的苯基或对氯取代的苯基；所述的环烷基包括环丁基。
进一步的是，所述的3-6元含一个N、O或S原子的杂环包括以下基团：
进一步的是，所述反应的条件为：反应温度为25℃，反应时间为3-24h。
进一步的是，所述化合物Ⅰ和化合物Ⅱ的摩尔比为1:1.3。
进一步的是，所述催化剂的用量为化合物Ⅰ摩尔量的1％～ 10％，优选为5％(实施例中以催化剂用量为化合物Ⅰ摩尔量的5％为例)。
进一步的是，所述添加剂与化合物Ⅰ的摩尔比为1:1。
本发明的目的之二是提供由上述方法制备得到的如式<Ⅲ>所示的具有呋喃-2(5H)-酮骨架的化合物。如本发明的实施例所示，本发明提供了一系列已被成功合成的化合物Ⅲ，并对这一系列化合物进行了表征。
本发明的有益效果如下：
本发明开发出了一类铑催化C–H烯化/导向基迁移/内酯化串联反应，成功制备了一系列具有呋喃-2(5H)-酮骨架的化合物。该合成方法具有底物适用范围广、区域选择性和立体选择性高、产率良好、官能团耐受性好、反应步骤经济、反应条件温和等优点，且可以放大到克级规模，具有较好的应用价值，同时具有广阔的应用前景。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合实施例对本发明进行具体描述，有必要指出的是，以下实施例仅仅用于对本发明进行解释和说明，并不用于限定本发明。本领域技术人员根据上述发明内容所做出的一些非本质的改进和调整，仍属于本发明的保护范围。
实施例1
反应条件的优化：以吲哚1aa和4-羟基壬-2-炔酸甲酯2aa为模板底物，按照表1所示步骤对反应条件进行优化。
首先，以NaOAc为添加剂，在一系列金属催化剂的催化下，1aa 和2aa在1,4-dioxane(1,4-二氧六环)中于25℃反应5h(序号1-6)。结果表明，当以[Cp*RhCl2]2为催化剂时，能以88％的产率获得目标C–H 烯化/导向基迁移/内酯化串联反应产物3aa，并伴随着少量的氧化副产物4aa的生成(序号6)。
然后，分别以[Cp*RhCl2]2和NaOAc为催化剂和添加剂对溶剂进行筛选(序号7-10)，结果表明，1,4-dioxane仍然是最佳反应溶剂。
随后，在最佳反应溶剂1,4-dioxane中考察了各种添加剂(序号 11-15)，相比之下，NaOAc仍然是最有效的添加剂。
最后，进行了空白实验(序号16和17)。结果表明，[Cp*RhCl2]2和NaOAc均不可或缺，[Cp*RhCl2]2/NaOAc催化体系是成功实现该 C–H烯化/导向基迁移/内酯化串联反应的关键。
表1.反应条件优化a
a反应条件：1aa(0.25mmol)，2aa(0.325mmol)，催化剂(5mol％)，添加剂(0.25mmol)，溶剂(4.0mL)，反应温度25℃，反应时间5h；b指分离产率。n-Pent为正戊基，1,4-dioxane为1,4-二氧六环，Toluene为甲苯，DCM为二氯甲烷，DCE 为1,2-二氯乙烷，THF为四氢呋喃，trace表示痕量。
实施例2
底物适用范围考察：
在上述最佳反应条件下(序号6)，按照表2所示，考查了铑催化C–H烯化/导向基迁移/内酯化串联反应的底物适用范围，制备了一系列具有呋喃-2(5H)-酮骨架的化合物3。首先以4-羟基壬-2-炔酸甲酯 2aa为偶联组分，考察了吲哚或吡咯底物的适用范围，合成了化合物 3aa-3bf，并统计其产率。然后考察了4-羟基-2-炔酸酯类底物的适用范围，合成了化合物3bg-3bt，并统计其产率。考查结果见表2。
具体方法为：向25mL舒伦克反应管中依次加入吲哚1(0.25 mmol)、[Cp*RhCl2]2(5mol％)和NaOAc(0.25mmol)，再向其中加入含4-羟基-2-炔酸酯2(0.325mmol)的1,4-二氧六环(4.0mL)溶液，然后用盖子密封反应管，将得到的反应混合物在25℃下进行搅拌反应，具体反应时间如表2所示。反应结束后，先减压浓缩去除反应溶剂，所得残留物在硅胶上通过快速色谱纯化，得到目标产物3。
表2.底物适用范围a,b
a反应条件：底物1(0.25mmol)，底物2(0.325mmol)，[Cp*RhCl2]2(5mol％)， NaOAc(0.25mmol)，1,4-二氧六环(4.0mL)，反应温度25℃，反应时间3-24h；
b分离产率。n-Pent为正戊基，Et为乙基，n-Bu为正丁基，Ph为苯基。
上述结果表明，本发明提供的铑催化C–H烯化/导向基迁移/内酯化串联反应具有底物适用范围广、区域选择性和立体选择性高、产率良好、官能团耐受性好、反应步骤经济、反应条件温和等优点，可以高效地合成一系列具有呋喃-2(5H)-酮骨架的化合物3。
实施例3
克级放大反应实验：
按照如下的反应式所示反应条件进行克级放大反应，在100mL 圆底烧瓶中依次加入吲哚1aa(6mmol)、[Cp*RhCl2]2(5mol％)和 NaOAc(6mmol)，然后向其中加入含有4-羟基壬-2-炔酸甲酯2aa(7.8 mmol)的1,4-二氧六环(40.0mL)溶液，用塞子密封烧瓶，将得到的反应混合物在25℃下搅拌反应5h。反应结束后，先减压浓缩去除溶剂，所得残留物在硅胶上用快速色谱法纯化(石油/乙酸乙酯:16/1→石油/ 乙酸乙酯:8/1)，能以90％的产率得到1.85g黄色无定形固体，即为目标产物3aa。放大反应实验结果证明：该反应可以放大到克级规模，进一步证明这类反应具有较好的应用前景。
实施例4
对上述实施例2和3中制备的一系列具有呋喃-2(5H)-酮骨架的化合物(化合物一至四十六)的具体表征：
采用氢谱+碳谱+高分辨质谱进行表征，所得系列化合物的表征结果如下：
化合物一(3aa)：
4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(75.4mg，产率88％)，熔点(mp)118-119℃。1H NMR(500MHz,DMSO-d6)δ12.41(s,1H),11.55(s,1H),7.71(d,J＝8.1Hz, 1H),7.65(d,J＝8.3Hz,1H),7.36-7.27(m,2H),7.15-7.08(m,1H),5.86(dd,J＝7.7, 2.9Hz,1H),3.76(s,3H),2.16-2.05(m,1H),1.78-1.69(m,1H),1.47-1.37(m,1H), 1.30-1.20(m,5H),0.81(t,J＝6.8Hz,3H)；13C NMR(125MHz,DMSO-d6)δ170.51, 160.50,159.15,137.95,127.30,127.01,125.99,122.04,120.78,112.83,112.52, 110.81,80.94,63.60,35.70,30.82,23.55,21.91,13.79；HRMS(ESI)m/z:[M+H]+ Calcd for C19H23N2O4343.1652；Found343.1651.
化合物二(3ab)：
4-(4-氟-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(4-fluoro-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(79.7mg，产率88％)，熔点(mp)104-105℃。1H NMR(500MHz,DMSO-d6)δ12.60(s,1H),11.57(s,1H),7.51(d,J＝8.3Hz, 1H),7.37(d,J＝1.0Hz,1H),7.32-7.26(m,1H),6.90(dd,J＝10.5,7.8Hz,1H),5.89 (dd,J＝7.7,3.0Hz,1H),3.76(s,3H),2.15-2.05(m,1H),1.76-1.67(m,1H), 1.48-1.37(m,1H),1.30-1.18(m,5H),0.81(t,J＝6.9Hz,3H)；13C NMR(125MHz, DMSO-d6)δ170.19,159.93,158.85,155.96(d,JC-F＝248.4Hz),140.03(d,JC-F＝ 9.8Hz),127.35,126.34(d,JC-F＝7.6Hz),116.90(d,JC-F＝22.3Hz),113.85,109.44 (d,JC-F＝3.5Hz),105.82,104.73(d,JC-F＝18.1Hz),80.96,63.56,35.38,30.78, 23.50,21.86,13.74；HRMS(ESI)m/z:[M+H]+Calcd forC19H22FN2O4361.1558； Found 361.1557.
化合物三(3ac)：
4-(4-氯-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(4-chloro-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(73.8mg，产率78％)，mp 155-156℃。
1H NMR(600MHz,DMSO-d6)δ12.60(s,1H),11.61(s,1H),7.65(d,J＝8.3Hz, 1H),7.33-7.26(m,2H),7.20(d,J＝7.5Hz,1H),5.93(dd,J＝7.7,2.9Hz,1H),3.76 (s,3H),2.13-2.02(m,1H),1.75-1.65(m,1H),1.46-1.38(m,1H),1.28-1.20(m,5H), 0.80(t,J＝6.5Hz,3H)；13C NMR(150MHz,DMSO-d6)δ170.13,159.68,158.80, 138.45,127.71,126.30,126.03,125.72,120.21,114.48,112.09,107.84,80.91,63.54, 35.22,30.80,23.47,21.89,13.78；HRMS(ESI)m/z:[M+H]+Calcd for C19H22ClN2O4377.1263；Found 377.1262.
化合物四(3ad)：
4-(4-溴-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(4-bromo-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(94.9mg，产率90％)，mp 178-180℃。
1H NMR(600MHz,CDCl3)δ13.37(s,1H),11.27(s,1H),7.44(d,J＝8.3Hz,1H), 7.32(d,J＝7.4Hz,1H),7.23-7.17(m,1H),7.01(s,1H),5.61(dd,J＝8.0,2.8Hz, 1H),3.93(s,3H),2.36-2.27(m,1H),1.91-1.82(m,1H),1.56-1.41(m,2H),1.38-1.29 (m,4H),0.88(t,J＝6.9Hz,3H)；13C NMR(150MHz,CDCl3)δ172.51,162.30, 160.24,138.67,128.79,127.72,127.57,124.15,116.20,112.22,111.01,110.91,82.07, 64.89,37.42,31.39,24.29,22.55,14.07；HRMS(ESI)m/z:[M+H]+Calcd for C19H22BrN2O4421.0757；Found421.0757.
化合物五(3ae)：
4-(5-氟-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(5-fluoro-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(66.8mg，产率74％)，mp124-125℃。
1H NMR(600MHz,DMSO-d6)δ12.45(s,1H),11.58(s,1H),7.70(dd,J＝9.0,4.5 Hz,1H),7.47(dd,J＝9.5,2.2Hz,1H),7.27(s,1H),7.21-7.15(m,1H),5.86(dd,J＝7.8,2.8Hz,1H),3.76(s,3H),2.13-2.05(m,1H),1.75-1.65(m,1H),1.45-1.37(m, 1H),1.27-1.19(m,5H),0.81(t,J＝6.8Hz,3H)；13C NMR(150MHz,DMSO-d6)δ170.31,160.10,158.95,157.43(d,JC-F＝234.9Hz),134.74,128.51,127.30(d,JC-F＝ 10.6Hz),114.85(d,JC-F＝27.1Hz),114.40(d,JC-F＝9.7Hz),113.43,110.34(d,JC-F＝5.7Hz),105.79(d,JC-F＝23.3Hz),80.95,63.58,35.47,30.82,23.60,21.91,13.78； HRMS(ESI)m/z:[M+H]+Calcd forC19H22FN2O4361.1558；Found 361.1557.
化合物六(3af)：
4-(5-氯-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(5-chloro-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(73.3mg，产率78％)，mp141-142℃。
1H NMR(600MHz,DMSO-d6)δ12.49(s,1H),11.59(s,1H),7.77(s,1H),7.70(d, J＝8.8Hz,1H),7.30(d,J＝8.8Hz,1H),7.26(s,1H),5.86(dd,J＝7.6,2.4Hz,1H), 3.75(s,3H),2.12-2.02(m,1H),1.74-1.66(m,1H),1.45-1.35(m,1H),1.27-1.20(m, 5H),0.80(t,J＝6.3Hz,3H)；13C NMR(150MHz,DMSO-d6)δ170.22,159.93, 158.85,136.26,128.30,128.17,125.78,125.22,120.85,114.63,113.87,109.79, 80.96,63.58,35.34,30.81,23.58,21.90,13.79；HRMS(ESI)m/z:[M+H]+Calcd for C19H22ClN2O4377.1263；Found377.1262.
化合物七(3ag)：
4-(5-溴-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(5-bromo-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(71.1mg，产率68％)，mp139-140℃。
1H NMR(500MHz,DMSO-d6)δ12.48(s,1H),11.57(s,1H),7.92(d,J＝1.4Hz, 1H),7.65(d,J＝8.8Hz,1H),7.40(dd,J＝8.8,1.8Hz,1H),7.25(s,1H),5.85(dd,J ＝7.8,2.9Hz,1H),3.76(s,3H),2.14-2.03(m,1H),1.75-1.65(m,1H),1.47-1.36(m, 1H),1.30-1.17(m,5H),0.81(t,J＝6.8Hz,3H)；13C NMR(125MHz,DMSO-d6)δ 170.20,159.87,158.83,136.44,128.90,128.21,128.10,123.99,114.97,113.95, 113.17,109.63,80.95,63.57,35.30,30.79,23.55,21.87,13.77；HRMS(ESI)m/z:[M +H]+Calcd forC19H22BrN2O4421.0757；Found421.0758.
化合物八(3ah)：
4-(5-碘-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(5-iodo-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(80.1mg，产率68％)，mp 127-128℃。
1H NMR(500MHz,DMSO-d6)δ12.46(s,1H),11.56(s,1H),8.11(s,1H),7.57-7.50(m,2H),7.23(d,J＝1.6Hz,1H),5.85(dd,J＝7.8,2.9Hz,1H),3.75(s,3H), 2.11-2.05(m,1H),1.75-1.66(m,1H),1.44-1.37(m,1H),1.29-1.21(m,5H),0.81(t,J ＝6.8Hz,3H)；13CNMR(125MHz,DMSO-d6)δ170.22,159.87,158.85,136.74, 133.52,130.31,129.82,127.62,115.24,113.85,109.29,84.67,80.94,63.57,35.31, 30.79,23.53,21.87,13.77；HRMS(ESI)m/z:[M+H]+Calcd for C19H22IN2O4 469.0619；Found 469.0622.
化合物九(3ai)：
4-(6-氟-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(6-fluoro-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(80.1mg，产率89％)，mp95-96℃。
1H NMR(600MHz,DMSO-d6)δ12.51(s,1H),11.55(s,1H),7.74(dd,J＝8.7,5.6 Hz,1H),7.54(d,J＝9.2Hz,1H),7.34(s,1H),7.05-6.95(m,1H),5.85(dd,J＝7.7, 2.6Hz,1H),3.76(s,3H),2.14-2.06(m,1H),1.76-1.68(m,1H),1.46-1.37(m,1H), 1.28-1.19(m,5H),0.81(t,J＝6.6Hz,3H)；13C NMR(150MHz,DMSO-d6)δ170.48, 161.27(d,JC-F＝241.0Hz),160.25,159.11,138.14(d,JC-F＝13.7Hz),127.83(d,JC-F＝3.4Hz),124.26,123.78(d,JC-F＝10.6Hz),112.22,111.24,110.34(d,JC-F＝25.8 Hz),98.61(d,JC-F＝26.4Hz),80.89,63.60,35.79,30.82,23.58,21.92,13.80；HRMS (ESI)m/z:[M+H]+Calcd forC19H22FN2O4361.1558；Found 361.1558.
化合物十(3aj)：
4-(6-氯-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(6-chloro-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(78.3mg，产率83％)，mp90-91℃。
1H NMR(600MHz,DMSO-d6)δ12.46(s,1H),11.56(s,1H),7.81(s,1H),7.72(d,J ＝8.6Hz,1H),7.33(s,1H),7.12(dd,J＝8.6,1.5Hz,1H),5.85(dd,J＝7.7,2.5Hz, 1H),3.76(s,3H),2.14-2.05(m,1H),1.76-1.67(m,1H),1.45-1.38(m,1H),1.30-1.18 (m,5H),0.81(t,J＝6.5Hz,3H)；13C NMR(150MHz,DMSO-d6)δ170.32,160.09, 158.93,138.15,130.42,127.95,125.96,123.48,121.37,113.18,112.56,110.81, 80.96,63.60,35.54,30.81,23.58,21.90,13.79；HRMS(ESI)m/z:[M+H]+Calcd for C19H22ClN2O4377.1263；Found377.1261.
化合物十一(3ak)：
4-(6-溴-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(6-bromo-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(94.4mg，产率90％)，mp81-82℃。
1H NMR(600MHz,CDCl3)δ13.20(s,1H),11.25(s,1H),7.66(s,1H),7.52(d,J＝8.6Hz,1H),7.23(dd,J＝8.6,1.5Hz,1H),6.97(d,J＝0.6Hz,1H),5.54(dd,J＝8.2, 2.8Hz,1H),3.92(s,3H),2.30-2.22(m,1H),1.87-1.78(m,1H),1.53-1.44(m,2H), 1.34-1.27(m,4H),0.87(t,J＝6.9Hz,3H)；13C NMR(150MHz,CDCl3)δ172.55, 162.19,160.27,139.10,127.90,126.47,125.09,123.46,121.15,115.80,111.11, 110.47,82.02,64.85,37.53,31.43,24.44,22.55,14.06；HRMS(ESI)m/z:[M+H]+ Calcd for C19H22BrN2O4421.0757；Found421.0756.
化合物十二(3al)：
4-(7-氟-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(7-fluoro-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(77.6mg，产率86％)，mp 136-138℃。
1H NMR(600MHz,CDCl3)δ13.38(s,1H),11.25(s,1H),7.47-7.41(m,1H), 7.08-7.00(m,3H),5.56(dd,J＝8.1,2.7Hz,1H),3.93(s,3H),2.32-2.24(m,1H), 1.88-1.79(m,1H),1.54-1.44(m,2H),1.35-1.28(m,4H),0.87(t,J＝6.9Hz,3H)；13C NMR(150MHz,CDCl3)δ172.50,162.27,160.06,149.97(d,JC-F＝249.2Hz), 130.96(d,JC-F＝4.9Hz),127.96,127.83(d,JC-F＝14.3Hz),121.41(d,JC-F＝5.6Hz), 117.95(d,JC-F＝4.1Hz),111.18(d,JC-F＝2.5Hz),111.02,110.91(d,JC-F＝15.8Hz), 82.05,64.91,37.43,31.44,24.40,22.55,14.06；HRMS(ESI)m/z:[M+H]+Calcd for C19H22FN2O4361.1558；Found 361.1557.
化合物十三(3am)：
N-甲氧基-4-(4-甲基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(4-methyl-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(80.4mg，产率90％)，mp 122-123℃。
1H NMR(600MHz,CDCl3)δ13.12(s,1H),11.25(s,1H),7.32(d,J＝8.4Hz,1H),7.28-7.24(m,1H),7.01(s,1H),6.93(d,J＝6.9Hz,1H),5.59(dd,J＝8.0,2.9Hz, 1H),3.93(s,3H),2.58(s,3H),2.35-2.25(m,1H),1.91-1.82(m,1H),1.56-1.43(m, 2H),1.36-1.28(m,4H),0.88(t,J＝7.0Hz,3H)；13C NMR(150MHz,CDCl3)δ 172.84,162.49,160.54,138.74,132.08,128.31,127.59,126.83,121.20,110.59, 109.92,109.41,81.95,64.85,37.76,31.44,24.25,22.54,18.90,14.06；HRMS(ESI) m/z:[M+H]+Calcd for C20H25N2O4357.1809；Found 357.1805.
化合物十四(3an)：
N-甲氧基-4-(4-甲氧基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(4-methoxy-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(88.0mg，产率95％)，mp137-138℃。
1H NMR(600MHz,CDCl3)δ13.11(s,1H),11.24(s,1H),7.29-7.26(m,1H),7.12(s,1H),7.07(d,J＝8.4Hz,1H),6.46(d,J＝7.7Hz,1H),5.53(dd,J＝8.1,2.7Hz,1H), 3.97(s,3H),3.92(s,3H),2.31-2.24(m,1H),1.88-1.80(m,1H),1.53-1.40(m,2H), 1.35-1.26(m,4H),0.87(t,J＝6.9Hz,3H)；13C NMR(150MHz,CDCl3)δ172.88, 162.28,160.61,154.41,140.13,128.53,126.28,120.05,109.20,108.99,105.87, 99.61,81.99,64.83,55.46,37.79,31.47,24.39,22.59,14.07；HRMS(ESI)m/z:[M+ H]+Calcd for C20H25N2O5373.1758；Found 373.1757.
化合物十五(3ao)：
N-甲氧基-4-(5-甲基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(5-methyl-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(73.7mg，产率83％)，mp 130-131℃。
1H NMR(500MHz,DMSO-d6)δ12.34(s,1H),11.51(s,1H),7.54(d,J＝8.5Hz, 1H),7.47(s,1H),7.21(d,J＝0.9Hz,1H),7.16(dd,J＝8.5,1.3Hz,1H),5.85(dd,J ＝7.7,2.9Hz,1H),3.76(s,3H),2.38(s,3H),2.16-2.06(m,1H),1.79-1.68(m,1H), 1.47-1.37(m,1H),1.30-1.19(m,5H),0.81(t,J＝6.9Hz,3H)；13C NMR(125MHz, DMSO-d6)δ170.56,160.59,159.21,136.51,129.58,128.11,127.57,126.96,121.00, 112.54,111.91,110.29,80.87,63.56,35.78,30.79,23.49,21.86,21.07,13.76；HRMS (ESI)m/z:[M+H]+Calcd for C20H25N2O4357.1809；Found 357.1806.
化合物十六(3ap)：
N-甲氧基-4-(5-甲氧基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(5-methoxy-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(84.7mg，产率91％)，mp 101-102℃。
1H NMR(600MHz,CDCl3)δ13.12(s,1H),11.24(s,1H),7.39(d,J＝9.0Hz,1H), 7.05(dd,J＝9.0,1.7Hz,1H),7.01(s,1H),6.92(s,1H),5.55(dd,J＝8.1,2.3Hz, 1H),3.92(s,3H),3.85(s,3H),2.32-2.23(m,1H),1.87-1.79(m,1H),1.54-1.43(m, 2H),1.36-1.28(m,4H),0.88(t,J＝6.8Hz,3H)；13C NMR(150MHz,CDCl3)δ 172.87,162.46,160.62,155.15,134.63,128.16,127.55,120.03,114.08,110.52, 109.02,101.12,81.99,64.85,55.71,37.75,31.48,24.46,22.58,14.09；HRMS(ESI) m/z:[M+H]+Calcd for C20H25N2O5373.1758；Found 373.1759.
化合物十七(3aq)：
4-(5-乙氧基-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(5-ethoxy-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(82.0mg，产率85％)，mp 97-98℃。
1H NMR(600MHz,CDCl3)δ13.10(s,1H),11.24(s,1H),7.38(d,J＝9.0Hz,1H), 7.05(dd,J＝9.0,2.2Hz,1H),7.00(s,1H),6.91(s,1H),5.55(dd,J＝8.1,2.6Hz, 1H),4.05(q,J＝7.0Hz,2H),3.92(s,3H),2.32-2.24(m,1H),1.88-1.79(m,1H), 1.55-1.47(m,2H),1.45(t,J＝6.9Hz,3H),1.36-1.27(m,4H),0.88(t,J＝6.9Hz, 3H)；13C NMR(150MHz,CDCl3)δ172.88,162.46,160.63,154.41,134.63,128.21, 127.52,120.45,114.02,110.52,108.95,102.08,81.98,64.85,63.97,37.75,31.47, 24.45,22.58,15.02,14.09；HRMS(ESI)m/z:[M+H]+Calcd for C21H27N2O5 387.1914；Found 387.1913.
化合物十八(3ar)：
N-甲氧基-4-(6-甲基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(6-methyl-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定型固体(88.1mg，产率99％),mp 113-114℃。
1H NMR(600MHz,CDCl3)δ12.98(s,1H),11.24(s,1H),7.54(d,J＝8.3Hz,1H), 7.26(s,1H),7.00-6.93(m,2H),5.53(dd,J＝8.2,2.8Hz,1H),3.92(s,3H),2.48(s, 3H),2.31-2.22(m,1H),1.88-1.78(m,1H),1.54-1.44(m,2H),1.36-1.28(m,4H), 0.87(t,J＝6.4Hz,3H)；13C NMR(150MHz,CDCl3)δ172.90,162.41,160.63, 139.40,137.98,126.89,125.90,123.87,121.94,112.43,111.52,108.88,81.94,64.82, 37.82,31.46,24.40,22.56,22.40,14.07；HRMS(ESI)m/z:[M+H]+Calcd for C20H25N2O4357.1809；Found 357.1804.
化合物十九(3as)：
N-甲氧基-4-(6-甲氧基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(6-methoxy-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(78.2mg，产率84％)，mp 99-100℃。
1H NMR(600MHz,CDCl3)δ13.11(s,1H),11.25(s,1H),7.52(d,J＝8.9Hz,1H), 6.96(s,1H),6.85(s,1H),6.80(dd,J＝8.9,2.1Hz,1H),5.51(dd,J＝8.2,2.7Hz, 1H),3.91(s,3H),3.86(s,3H),2.30-2.19(m,1H),1.88-1.79(m,1H),1.54-1.42(m, 2H),1.36-1.27(m,4H),0.87(t,J＝6.9Hz,3H)；13C NMR(150MHz,CDCl3)δ173.03,161.83,160.95,160.49,140.33,126.55,123.32,122.71,114.43,112.13, 107.63,93.44,81.75,64.80,55.57,37.96,31.47,24.40,22.57,14.07；HRMS(ESI) m/z:[M+H]+Calcd for C20H25N2O5373.1758；Found 373.1754.
化合物二十(3at)：
N-甲氧基-4-(7-甲氧基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(7-methoxy-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(61.3mg，产率66％)，mp 137-138℃。
1H NMR(600MHz,CDCl3)δ13.18(s,1H),11.24(s,1H),7.24(d,J＝8.2Hz,1H),7.07-7.02(m,1H),6.96(d,J＝2.0Hz,1H),6.72(d,J＝7.6Hz,1H),5.53(dd,J＝8.1,2.8Hz,1H),3.98(s,3H),3.93(s,3H),2.31-2.23(m,1H),1.87-1.78(m,1H), 1.53-1.41(m,2H),1.36-1.27(m,4H),0.87(t,J＝7.0Hz,3H)；13C NMR(150MHz, CDCl3)δ172.84,162.53,160.28,147.21,130.55,128.97,126.81,121.92,114.21, 111.26,109.76,105.16,81.98,64.89,55.51,37.58,31.45,24.35,22.56,14.07；HRMS (ESI)m/z:[M+H]+Calcd forC20H25N2O5373.1758；Found 373.1757.
化合物二十一(3au)：
4-(5-(呋喃-2-基)-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(5-(furan-2-yl)-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(86.6mg，产率85％)，mp 98-99℃。
1H NMR(600MHz,CDCl3)δ13.21(s,1H),11.26(s,1H),7.97(s,1H),7.69(dd,J＝8.7,1.4Hz,1H),7.51-7.46(m,2H),7.01(s,1H),6.62(d,J＝3.3Hz,1H),6.49(dd,J ＝3.2,1.8Hz,1H),5.57(dd,J＝8.2,2.7Hz,1H),3.93(s,3H),2.34-2.24(m,1H), 1.89-1.81(m,1H),1.56-1.45(m,2H),1.37-1.29(m,4H),0.88(t,J＝7.0Hz,3H)；13C NMR(150MHz,CDCl3)δ172.72,162.38,160.45,154.53,141.88,138.18,127.97, 127.94,124.79,124.47,116.87,113.38,111.83,111.45,109.87,104.34,82.06,64.88, 37.64,31.46,24.45,22.57,14.08；HRMS(ESI)m/z:[M-H]-Calcd for C23H23N2O5 407.1612；Found 407.1616.
化合物二十二(3av)：
N-甲氧基-2-羰基-5-戊基-4-(5-(噻吩-2-基)-1H-吲哚-2-基)-2,5-二氢呋喃-3-甲酰胺
N-methoxy-2-oxo-5-pentyl-4-(5-(thiophen-2-yl)-1H-indol-2-yl)-2,5-dihydrofuran-3-carboxam ide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(94.7mg，产率89％)，mp 121-122℃。
1H NMR(600MHz,CDCl3)δ13.22(s,1H),11.26(s,1H),7.88(s,1H),7.66(dd,J＝8.7,1.6Hz,1H),7.50(d,J＝8.7Hz,1H),7.30(dd,J＝3.5,0.9Hz,1H),7.27-7.26(m, 1H),7.09(dd,J＝5.0,3.6Hz,1H),7.01(d,J＝0.8Hz,1H),5.57(dd,J＝8.2,2.8Hz, 1H),3.93(s,3H),2.35-2.26(m,1H),1.89-1.81(m,1H),1.55-1.44(m,2H),1.39-1.26 (m,4H),0.89(t,J＝7.0Hz,3H)；13C NMR(150MHz,CDCl3)δ172.69,162.36, 160.42,145.08,138.24,128.18,128.17,128.14,128.07,126.45,124.39,122.77, 118.98,113.46,111.27,110.02,82.06,64.87,37.63,31.46,24.47,22.57,14.08； HRMS(ESI)m/z:[M-H]-Calcdfor C23H23N2O4S 423.1384；Found 423.1383.
化合物二十三(3aw)：
4-(5-氰基-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(5-cyano-1H-indol-2-yl)-N-methoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(74.8mg，产率81％)，mp 158-159℃。
1H NMR(600MHz,CDCl3)δ13.58(s,1H),11.28(s,1H),8.07(s,1H),7.60-7.53 (m,2H),7.08(s,1H),5.59(dd,J＝8.2,2.7Hz,1H),3.93(s,3H),2.33-2.24(m,1H), 1.90-1.80(m,1H),1.56-1.44(m,2H),1.38-1.28(m,4H),0.88(t,J＝6.9Hz,3H)；13C NMR(150MHz,CDCl3)δ172.14,161.91,159.93,139.40,129.42,128.61,128.44, 127.10,119.94,114.11,112.10,111.05,104.77,82.09,64.91,37.27,31.41,24.44, 22.54,14.04；HRMS(ESI)m/z:[M-H]-Calcd for C20H20N3O4366.1459；Found 366.1460.
化合物二十四(3ax)：
甲基2-(4-(甲氧基氨基甲酰)-5-羰基-2-戊基-2,5-二氢呋喃-3-基)-1H-吲哚-5-羧酸酯
methyl2-(4-(methoxycarbamoyl)-5-oxo-2-pentyl-2,5-dihydrofuran-3-yl)-1H-indole-5-carboxy late
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(95.4mg，产率95％)，mp 173-174℃。
1H NMR(600MHz,CDCl3)δ13.35(s,1H),11.26(s,1H),8.45(s,1H),8.02(dd,J＝8.8,1.5Hz,1H),7.50(d,J＝8.8Hz,1H),7.09(d,J＝0.7Hz,1H),5.58(dd,J＝8.2, 2.8Hz,1H),3.93(s,3H),3.93(s,3H),2.31-2.24(m,1H),1.87-1.79(m,1H), 1.55-1.43(m,2H),1.34-1.28(m,4H),0.87(t,J＝7.0Hz,3H)；13C NMR(150MHz, CDCl3)δ172.43,167.49,162.18,160.16,140.57,128.74,127.65,127.17,125.69, 123.52,112.75,112.32,110.96,82.05,64.87,52.21,37.46,31.41,24.41,22.53,14.05； HRMS(ESI)m/z:[M-H]-Calcd for C21H23N2O6399.1562；Found 399.1563.
化合物二十五(3ay)：
N-甲氧基-4-(3-甲基-1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(3-methyl-1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(27.4mg，产率31％)，mp 113-114℃。
1H NMR(600MHz,CDCl3)δ13.34(s,1H),11.35(s,1H),7.63(d,J＝8.2Hz,1H), 7.45(d,J＝8.4Hz,1H),7.38-7.32(m,1H),7.16-7.10(m,1H),5.77(dd,J＝6.1,2.0 Hz,1H),3.90(s,3H),2.56(s,3H),2.11-2.03(m,1H),1.67-1.60(m,1H),1.60-1.50 (m,2H),1.32-1.27(m,4H),0.87(t,J＝7.0Hz,3H)；13C NMR(150MHz,CDCl3)δ 172.87,164.69,161.04,138.23,129.22,127.43,125.02,121.11,120.52,120.47, 112.87,109.14,82.09,64.76,37.07,31.47,25.50,22.52,14.03,12.17；HRMS(ESI) m/z:[M+H]+Calcd forC20H25N2O4357.1809；Found 357.1808.
化合物二十六(3az)：
乙基2-(2-(4-(甲氧基氨基甲酰)-5-羰基-2-戊基-2,5-二氢呋喃-3-基)-1H-吲哚-3-基) 乙酸酯
ethyl2-(2-(4-(methoxycarbamoyl)-5-oxo-2-pentyl-2,5-dihydrofuran-3-yl)-1H-indol-3-yl)aceta te
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(10.6mg，产率10％)，mp 169-170℃。
1H NMR(600MHz,CDCl3)δ13.55(s,1H),11.32(s,1H),7.67(d,J＝7.7Hz,1H), 7.48(d,J＝8.4Hz,1H),7.38-7.33(m,1H),7.19-7.14(m,1H),5.96(dd,J＝8.4,2.4 Hz,1H),4.17-4.10(m,2H),4.07(d,J＝16.2Hz,1H),3.90(s,3H),3.83(d,J＝16.2 Hz,1H),2.12-2.05(m,1H),1.64-1.57(m,3H),1.33-1.28(m,4H),1.22(t,J＝7.1Hz, 3H),0.87(t,J＝7.0Hz,3H)；13C NMR(150MHz,CDCl3)δ172.65,170.31,164.57, 160.85,137.94,129.05,127.32,125.21,121.22,120.33,116.00,113.08,110.90, 81.78,64.80,61.72,37.13,32.34,31.47,25.37,22.55,14.27,14.05；HRMS(ESI)m/z: [M-H]-Calcd forC23H27N2O6427.1875；Found 427.1876.
化合物二十七(3ba)：
N-乙氧基-4-(1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-ethoxy-4-(1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(87.5mg，产率98％)，mp 90-91℃。
1H NMR(600MHz,CDCl3)δ13.15(s,1H),11.20(s,1H),7.67(d,J＝8.1Hz,1H), 7.49(d,J＝8.4Hz,1H),7.38-7.33(m,1H),7.17-7.11(m,1H),7.01(s,1H),5.56(dd, J＝8.2,2.6Hz,1H),4.13(q,J＝7.0Hz,2H),2.33-2.25(m,1H),1.88-1.80(m,1H), 1.55-1.43(m,2H),1.39(t,J＝7.0Hz,3H),1.34-1.26(m,4H),0.88(t,J＝6.9Hz, 3H)；13C NMR(150MHz,CDCl3)δ172.83,162.41,160.43,138.72,127.74,127.36, 127.20,122.31,121.38,113.06,111.21,109.92,82.01,72.81,37.70,31.45,24.45, 22.56,14.07,13.62；HRMS(ESI)m/z:[M+H]+Calcd for C20H25N2O4357.1809； Found 357.1806.
化合物二十八(3bb)：
4-(1H-吲哚-2-基)-N-异丙氧基-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
4-(1H-indol-2-yl)-N-isopropoxy-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:32/1→石油/乙酸乙酯:16/1)，得到黄色无定形固体(77.4mg，产率84％)，mp 85-86℃。
1H NMR(600MHz,CDCl3)δ13.16(s,1H),11.11(s,1H),7.65(d,J＝8.1Hz,1H), 7.48(d,J＝8.4Hz,1H),7.36-7.30(m,1H),7.15-7.10(m,1H),6.98(s,1H),5.52(dd, J＝8.2,2.6Hz,1H),4.36-4.24(m,1H),2.31-2.23(m,1H),1.86-1.79(m,1H), 1.55-1.43(m,2H),1.36(d,J＝6.2Hz,6H),1.33-1.25(m,4H),0.87(t,J＝6.8Hz, 3H)；13C NMR(150MHz,CDCl3)δ172.85,162.17,160.40,138.63,127.68,127.34, 127.06,122.23,121.27,113.00,111.05,109.97,81.92,78.80,37.63,31.39,24.42, 22.50,20.64,14.01；HRMS(ESI)m/z:[M-H]-Calcd for C21H25N2O4369.1820； Found 369.1826.
化合物二十九(3bc)：
N-(叔-丁氧基)-4-(1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-(tert-butoxy)-4-(1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:32/1→石油/乙酸乙酯:16/1)，得到黄色粘稠油状物(34.7mg，产率36％)。
1H NMR(600MHz,CDCl3)δ13.22(s,1H),10.96(s,1H),7.66(d,J＝8.1Hz,1H), 7.49(d,J＝8.4Hz,1H),7.36-7.31(m,1H),7.16-7.10(m,1H),6.99(s,1H),5.55(dd, J＝8.3,2.6Hz,1H),2.33-2.25(m,1H),1.88-1.80(m,1H),1.55-1.47(m,2H),1.40(s, 9H),1.35-1.27(m,4H),0.88(t,J＝6.9Hz,3H)；13C NMR(150MHz,CDCl3)δ 173.04,162.07,160.73,138.68,127.71,127.43,127.05,122.24,121.28,113.06, 111.00,110.14,83.30,81.98,37.70,31.44,26.41,24.50,22.54,14.05；HRMS(ESI) m/z:[M-H]-Calcd forC22H27N2O4383.1976；Found 383.1982.
化合物三十(3bd)：
N-(苄氧基)-4-(1H-吲哚-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-(benzyloxy)-4-(1H-indol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:32/1→石油/乙酸乙酯:16/1)，得到黄色无定形固体(78.2mg，产率75％)，mp 142-143℃。
1H NMR(600MHz,CDCl3)δ13.14(s,1H),11.19(s,1H),7.68(d,J＝8.1Hz,1H), 7.53(d,J＝8.4Hz,1H),7.49(d,J＝7.4Hz,2H),7.45-7.34(m,4H),7.19-7.13(m, 1H),7.02(s,1H),5.56(dd,J＝8.2,2.6Hz,1H),5.15-4.98(m,2H),2.33-2.24(m, 1H),1.89-1.79(m,1H),1.54-1.42(m,2H),1.37-1.26(m,4H),0.88(t,J＝6.9Hz, 3H)；13C NMR(150MHz,CDCl3)δ172.70,162.43,160.41,138.74,134.76,129.28, 129.13,128.86,127.76,127.37,127.23,122.34,121.41,113.10,111.24,109.94, 82.01,78.91,37.68,31.45,24.43,22.57,14.07；HRMS(ESI)m/z:[M+H]+Calcd for C25H27N2O4419.1965；Found419.1963.
化合物三十一(3be)：
N-甲氧基-2-羰基-5-戊基-4-(1H-吡咯-2-基)-2,5-二氢呋喃-3-甲酰胺
N-methoxy-2-oxo-5-pentyl-4-(1H-pyrrol-2-yl)-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色粘稠油状物(46.9mg，产率64％)。
1H NMR(600MHz,CDCl3)δ13.61(s,1H),11.17(s,1H),7.23(s,1H),6.77(d,J＝1.3Hz,1H),6.46-6.39(m,1H),5.39(dd,J＝8.2,2.5Hz,1H),3.86(s,3H),2.22-2.11 (m,1H),1.79-1.71(m,1H),1.49-1.41(m,2H),1.32-1.25(m,4H),0.86(t,J＝6.9Hz, 3H)；13CNMR(150MHz,CDCl3)δ173.24,161.56,161.37,127.66,123.37,118.76, 112.79,104.92,81.45,64.68,37.57,31.39,24.37,22.48,14.02；HRMS(ESI)m/z:[M +H]+Calcd forC15H21N2O4293.1496；Found 293.1493.
化合物三十二(3bf)：
N-甲氧基-4-(5-甲基-1H-吡咯-2-基)-2-羰基-5-戊基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(5-methyl-1H-pyrrol-2-yl)-2-oxo-5-pentyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(32.3mg，产率42％)，mp 95-96℃。
1H NMR(600MHz,CDCl3)δ13.43(s,1H),11.18(s,1H),6.72(dd,J＝3.8,2.2Hz,1H),6.20-6.16(m,1H),5.35(dd,J＝8.3,2.8Hz,1H),3.87(s,3H),2.40(s,3H), 2.17-2.09(m,1H),1.79-1.71(m,1H),1.49-1.42(m,2H),1.33-1.27(m,4H),0.87(t,J ＝7.0Hz,3H)；13C NMR(150MHz,CDCl3)δ173.58,161.91,160.56,140.01,122.48, 120.43,112.70,102.57,81.16,64.82,37.98,31.47,24.36,22.55,14.08,14.00；HRMS (ESI)m/z:[M+H]+Calcd for C16H23N2O4307.1652；Found 307.1648.
化合物三十三(3bg)：
4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-2,5-二氢呋喃-3-甲酰胺
4-(1H-indol-2-yl)-N-methoxy-2-oxo-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:8/1→石油/乙酸乙酯:4/1)，得到黄色粘稠油状物(55.6mg，产率82％)。
1H NMR(600MHz,DMSO-d6)δ12.40(s,1H),11.48(s,1H),7.72-7.64(m,2H), 7.35-7.27(m,2H),7.14-7.07(m,1H),5.58(s,2H),3.77(s,3H)；13C NMR(150MHz, DMSO-d6)δ171.80,159.06,158.24,138.01,127.21,126.90,126.05,121.97,120.82, 112.93,111.37,110.05,70.45,63.64；HRMS(ESI)m/z:[M-H]-Calcd for C14H11N2O4271.0724；Found271.0728.
化合物三十四(3bh)：
5-乙基-4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-2,5-二氢呋喃-3-甲酰胺
5-ethyl-4-(1H-indol-2-yl)-N-methoxy-2-oxo-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(58.2mg，产率78％)，mp 148-149℃。
1H NMR(600MHz,DMSO-d6)δ12.41(s,1H),11.57(s,1H),7.70(dd,J＝8.1,0.6 Hz,1H),7.65(dd,J＝8.4,0.8Hz,1H),7.35-7.30(m,2H),7.14-7.09(m,1H),5.85 (dd,J＝7.1,3.2Hz,1H),3.76(s,3H),2.23-2.14(m,1H),1.84-1.76(m,1H),0.87(t, J＝7.3Hz,3H)；13CNMR(150MHz,DMSO-d6)δ170.53,160.11,159.12,137.96, 127.30,126.98,125.99,122.02,120.79,112.83,112.81,110.86,81.58,63.60,28.79, 8.22；HRMS(ESI)m/z:[M-H]-Calcdfor C16H15N2O4299.1037；Found 299.1039.
化合物三十五(3bi)：
5-丁基-4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-2,5-二氢呋喃-3-甲酰胺
5-butyl-4-(1H-indol-2-yl)-N-methoxy-2-oxo-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(50.8mg，产率62％)，mp 96-97℃。
1H NMR(600MHz,CDCl3)δ13.12(s,1H),11.25(s,1H),7.67(d,J＝8.1Hz,1H), 7.49(d,J＝8.4Hz,1H),7.39-7.33(m,1H),7.18-7.12(m,1H),7.02(d,J＝0.8Hz, 1H),5.57(dd,J＝8.1,2.8Hz,1H),3.93(s,3H),2.35-2.25(m,1H),1.90-1.81(m, 1H),1.53-1.42(m,2H),1.40-1.30(m,2H),0.90(t,J＝7.2Hz,3H)；13C NMR(150 MHz,CDCl3)δ172.76,162.55,160.44,138.75,127.75,127.31,127.28,122.34, 121.43,113.05,111.30,109.82,82.01,64.85,37.39,26.71,22.44,13.96；HRMS(ESI) m/z:[M-H]-Calcd for C18H19N2O4327.1350；Found 327.1355.
化合物三十六(3bj)：
5-苯甲基-4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-2,5-二氢呋喃-3-甲酰胺
5-benzyl-4-(1H-indol-2-yl)-N-methoxy-2-oxo-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(62.0mg，产率68％)，mp 168-169℃。
1H NMR(600MHz,DMSO-d6)δ12.48(s,1H),11.44(s,1H),7.76(d,J＝8.1Hz, 1H),7.69(d,J＝8.3Hz,1H),7.52(s,1H),7.37-7.34(m,1H),7.28-7.23(m,3H), 7.16-7.11(m,3H),6.17(dd,J＝7.2,3.5Hz,1H),3.71(s,3H),3.50(dd,J＝14.6,3.3 Hz,1H),3.10(dd,J＝14.6,7.3Hz,1H)；13C NMR(150MHz,DMSO-d6)δ170.26, 159.86,158.92,138.04,135.08,129.56,128.14,127.42,127.14,126.92,126.10, 122.15,120.84,112.93,112.81,111.28,80.71,63.55,41.43；HRMS(ESI)m/z:[M- H]-Calcd for C21H17N2O4361.1194；Found361.1197.
化合物三十七(3bk)：
4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-5-苯基-2,5-二氢呋喃-3-甲酰胺
4-(1H-indol-2-yl)-N-methoxy-2-oxo-5-phenyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(49.0mg，产率56％)，mp 166-167℃。
1H NMR(600MHz,DMSO-d6)δ12.40(s,1H),11.68(s,1H),7.61(d,J＝8.4Hz, 1H),7.56(d,J＝8.1Hz,1H),7.52(d,J＝7.4Hz,2H),7.44-7.36(m,3H),7.30-7.24 (m,1H),7.07-7.01(m,1H),6.95-6.88(m,2H),3.82(s,3H)；13C NMR(150MHz, DMSO-d6)δ170.45,159.05,158.59,137.70,136.61,129.62,129.13,127.82,127.09, 126.99,126.05,121.89,120.75,113.04,112.79,111.57,82.03,63.65；HRMS(ESI) m/z:[M-H]-Calcd forC20H15N2O4347.1037；Found 347.1039.
化合物三十八(3bl)：
4-(4-氟-1H-吲哚-2-基)-N-甲氧基-2-羰基-5-苯基-2,5-二氢呋喃-3-甲酰胺
4-(4-fluoro-1H-indol-2-yl)-N-methoxy-2-oxo-5-phenyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:8/1→石油/乙酸乙酯:4/1)，得到黄色无定形固体(44.2mg，产率48％)，mp 181-182℃。
1H NMR(600MHz,CDCl3)δ13.32(s,1H),11.34(s,1H),7.44-7.39(m,3H), 7.39-7.35(m,2H),7.25-7.19(m,2H),6.76(d,J＝1.7Hz,1H),6.72-6.67(m,1H), 6.44(s,1H),3.97(s,3H)；13C NMR(150MHz,CDCl3)δ172.29,160.17,160.10, 156.93(d,JC-F＝252.4Hz),140.50(d,JC-F＝9.2Hz),135.82,130.49,129.67,128.10, 127.74(d,JC-F＝7.7Hz),127.42,118.11(d,JC-F＝22.4Hz),111.33,109.09,108.97 (d,JC-F＝4.1Hz),105.13(d,JC-F＝18.4Hz),83.94,64.94；HRMS(ESI)m/z:[M- H]-Calcd for C20H14FN2O4365.0943；Found365.0942.
化合物三十九(3bm)：
N-甲氧基-4-(4-甲基-1H-吲哚-2-基)-2-羰基-5-苯基-2,5-二氢呋喃-3-甲酰胺
N-methoxy-4-(4-methyl-1H-indol-2-yl)-2-oxo-5-phenyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(63.2mg，产率70％)，mp 163-164℃。
1H NMR(600MHz,CDCl3)δ13.12(s,1H),11.33(s,1H),7.42-7.37(m,5H),7.28(d, J＝8.4Hz,1H),7.23-7.18(m,1H),6.83(d,J＝6.9Hz,1H),6.70(s,1H),6.45(s,1H), 3.97(s,3H),2.36(s,3H)；13C NMR(150MHz,CDCl3)δ172.60,160.46,160.32, 138.64,136.42,132.20,130.27,129.51,128.30,128.09,127.77,126.89,121.04, 112.18,110.47,109.98,83.85,64.91,18.66；HRMS(ESI)m/z:[M-H]-Calcd for C21H17N2O4361.1194；Found361.1196.
化合物四十(3bn)：
甲基2-(4-(甲氧基氨基甲酰)-5-羰基-2-苯基-2,5-二氢呋喃-3-基)-1H-吲哚-5-羧酸酯
methyl2-(4-(methoxycarbamoyl)-5-oxo-2-phenyl-2,5-dihydrofuran-3-yl)-1H-indole-5-carbox ylate
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:8/1→石油/乙酸乙酯:4/1)，得到黄色无定形固体(27.0mg，产率27％)，mp 203-204℃。
1H NMR(600MHz,CDCl3)δ13.36(s,1H),11.34(s,1H),8.26(s,1H),7.96(dd,J ＝8.8,1.0Hz,1H),7.45(d,J＝8.8Hz,1H),7.43-7.39(m,3H),7.39-7.35(m,2H), 6.76(s,1H),6.44(s,1H),3.97(s,3H),3.88(s,3H)；13C NMR(150MHz,CDCl3)δ 172.21,167.41,160.07,160.03,140.43,135.81,130.51,129.66,128.75,128.14, 127.74,127.09,125.84,123.36,114.53,112.64,111.63,83.96,64.94,52.15；HRMS (ESI)m/z:[M-H]-Calcd for C22H17N2O6405.1092；Found 405.1095.
化合物四十一(3bo)：
4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-5-(p-苯甲基)-2,5-二氢呋喃-3-甲酰胺
4-(1H-indol-2-yl)-N-methoxy-2-oxo-5-(p-tolyl)-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(71.0mg，产率78％)，mp 151-152℃。
1H NMR(600MHz,DMSO-d6)δ12.40(s,1H),11.68(s,1H),7.61(d,J＝8.4Hz, 1H),7.56(d,J＝8.1Hz,1H),7.39(d,J＝8.0Hz,2H),7.29-7.24(m,1H),7.21(d,J＝ 8.0Hz,2H),7.06-7.01(m,1H),6.90(s,1H),6.87(s,1H),3.82(s,3H),2.26(s,3H)；13C NMR(150MHz,DMSO-d6)δ170.54,159.11,158.74,139.22,137.70,133.71, 129.71,127.77,127.16,127.01,126.06,121.93,120.76,113.01,112.82,111.58,81.97, 63.67,20.79；HRMS(ESI)m/z:[M-H]-Calcd for C21H17N2O4361.1194；Found 361.1196.
化合物四十二(3bp)：
5-(4-氯苯基)-4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-2,5-二氢呋喃-3-甲酰胺
5-(4-chlorophenyl)-4-(1H-indol-2-yl)-N-methoxy-2-oxo-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(50.4mg，产率53％)，mp200-201℃。
1H NMR(600MHz,CDCl3)δ13.13(s,1H),11.28(s,1H),7.49(d,J＝8.1Hz,1H), 7.45(d,J＝8.4Hz,1H),7.42-7.36(m,2H),7.35-7.29(m,3H),7.11-7.03(m,1H), 6.66(s,1H),6.41(s,1H),3.97(s,3H)；13C NMR(150MHz,CDCl3)δ172.27,160.23, 159.85,138.77,136.42,134.81,129.87,129.56,127.70,127.65,127.13,122.52, 121.47,113.55,112.98,110.51,82.95,64.93；HRMS(ESI)m/z:[M-H]-Calcd for C20H14ClN2O4381.0648；Found 381.0651.
化合物四十三(3bq)：
8-(1H-吲哚-2-基)-N-甲氧基-6-羰基-5-氧杂螺[3.4]辛-7-烯-7-甲酰胺
8-(1H-indol-2-yl)-N-methoxy-6-oxo-5-oxaspiro[3.4]oct-7-ene-7-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(40.0mg，产率51％)，mp 183-184℃。
1H NMR(600MHz,DMSO-d6)δ12.78(s,1H),11.67(s,1H),7.79(d,J＝8.1Hz, 1H),7.66(d,J＝8.3Hz,1H),7.54(s,1H),7.37-7.32(m,1H),7.18-7.12(m,1H), 3.75(s,3H),3.06-2.96(m,2H),2.65-2.57(m,2H),2.40-2.26(m,2H)；13C NMR(150 MHz,DMSO-d6)δ168.84,160.20,159.45,137.66,127.56,127.04,126.24,122.26, 120.81,112.76,112.42,110.48,88.51,63.58,34.84,13.04；HRMS(ESI)m/z:[M+ H]+Calcd forC17H17N2O4313.1183；Found 313.1183.
化合物四十四(3br)：
N-甲氧基-8-(5-甲氧基-1H-吲哚-2-基)-6-羰基-5-氧杂螺[3.4]辛-7-烯-7-甲酰胺
N-methoxy-8-(5-methoxy-1H-indol-2-yl)-6-oxo-5-oxaspiro[3.4]oct-7-ene-7-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(36.0mg，产率42％)，mp 187-188℃。
1H NMR(600MHz,DMSO-d6)δ12.81(s,1H),11.64(s,1H),7.59(d,J＝9.0Hz, 1H),7.45(s,1H),7.22(s,1H),7.01(dd,J＝9.0,2.2Hz,1H),3.80(s,3H),3.75(s, 3H),3.06-2.95(m,2H),2.67-2.56(m,2H),2.40-2.24(m,2H)；13C NMR(150MHz, DMSO-d6)δ169.01,160.35,159.61,154.30,133.37,128.04,127.30,118.54,113.91, 111.31,110.07,101.47,88.45,63.60,55.22,34.99,12.96；HRMS(ESI)m/z:[M+ H]+Calcd forC18H19N2O5343.1288；Found 343.1287.
化合物四十五(3bs)：
8-(6-氯-1H-吲哚-2-基)-N-甲氧基-6-羰基-5-氧杂螺[3.4]辛-7-烯-7-甲酰胺
8-(6-chloro-1H-indol-2-yl)-N-methoxy-6-oxo-5-oxaspiro[3.4]oct-7-ene-7-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(47.1mg，产率54％)，mp 209-210℃。
1H NMR(600MHz,DMSO-d6)δ12.77(s,1H),11.67(s,1H),7.83(s,1H),7.80(d, J＝8.6Hz,1H),7.55(s,1H),7.15(dd,J＝8.6,1.5Hz,1H),3.74(s,3H),3.04-2.93 (m,2H),2.67-2.56(m,2H),2.39-2.24(m,2H)；13C NMR(150MHz,DMSO-d6)δ 168.67,159.71,159.22,137.87,130.67,127.95,126.26,123.71,121.44,113.24, 112.52,110.43,88.51,63.60,34.64,13.03；HRMS(ESI)m/z:[M+H]+Calcd for C17H16ClN2O4347.0793；Found 347.0792.
化合物四十六(3bt)：
4-(1H-吲哚-2-基)-N-甲氧基-2-羰基-5,5-二苯基-2,5-二氢呋喃-3-甲酰胺
4-(1H-indol-2-yl)-N-methoxy-2-oxo-5,5-diphenyl-2,5-dihydrofuran-3-carboxamide
将反应混合物直接在硅胶上进行快速色谱纯化(石油/乙酸乙酯:16/1→石油/乙酸乙酯:8/1)，得到黄色无定形固体(23.0mg，产率22％)，mp 222-223℃。
1H NMR(600MHz,CDCl3)δ13.71(s,1H),11.55(s,1H),7.47(d,J＝8.5Hz,1H),7.45-7.41(m,5H),7.40-7.35(m,6H),7.33-7.30(m,1H),7.05-7.01(m,1H),6.61(s, 1H),3.96(s,3H)；13C NMR(150MHz,DMSO-d6)δ171.81,163.94,160.93,138.64, 138.48,129.45,129.10,128.60,128.45,127.66,127.58,122.72,121.20,116.75, 112.99,110.80,93.38,64.84；HRMS(ESI)m/z:[M+H]+Calcd for C26H21N2O4 425.1496；Found 425.1490。
Claims (9)
1.一种具有呋喃-2(5H)-酮骨架的化合物的制备方法，其特征在于，所述具有呋喃-2(5H)-酮骨架的化合物结构式如式<Ⅲ>所示，所述制备方法包括如下步骤：
以式<Ⅰ>所示吲哚化合物和式<Ⅱ>所示4-羟基-2-炔酸酯化合物为底物，并以[Cp*RhCl2]2为催化剂、醋酸钠为添加剂、1,4-二氧六环为溶剂，反应得到式<Ⅲ>所示化合物；
其中，R1代表苯环上任意位置的取代基，其选自以下基团：氢、卤素、烷基、烷氧基、3-6元含一个N、O或S原子的杂环、氰基、酯基；
R2选自以下基团：氢、取代或未取代的烷基；
R3选自以下基团：取代或未取代烷基；
R4和R5各自独立地选自以下基团：氢、取代或未取代烷基、芳基；
R6选自烷基；
所述的取代指基团上的一个或多个氢原子被选自下组的任意基团取代：苯基、酯基。
2.根据权利要求1所述的制备方法，其特征在于，所述的卤素为F、Cl、Br或I。
3.根据权利要求1所述的制备方法，其特征在于，所述的烷基为甲基、乙基、异丙基、正丁基、叔丁基或正戊基；所述的烷氧基为甲氧基或乙氧基；所述的取代烷基为苄基或CH2CO2Et；所述的芳基为苯基、对甲基取代的苯基或对氯取代的苯基。
4.根据权利要求1所述的制备方法，其特征在于，所述的3-6元含一个N、O或S原子的杂环为以下基团：
5.根据权利要求1所述的制备方法，其特征在于，反应条件为：反应温度为25℃，反应时间为3-24h。
6.根据权利要求1所述的制备方法，其特征在于，所述化合物Ⅰ和化合物Ⅱ的摩尔比为1:1.3。
7.根据权利要求1所述的制备方法，其特征在于，所述催化剂的用量为化合物Ⅰ摩尔量的1％～10％。
8.根据权利要求7所述的制备方法，其特征在于，所述催化剂的用量为化合物Ⅰ摩尔量的5％。
9.根据权利要求1所述的制备方法，其特征在于，所述添加剂与化合物Ⅰ的摩尔比为1:1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111210020.8A CN113980004B (zh) | 2021-10-18 | 2021-10-18 | 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111210020.8A CN113980004B (zh) | 2021-10-18 | 2021-10-18 | 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113980004A CN113980004A (zh) | 2022-01-28 |
| CN113980004B true CN113980004B (zh) | 2023-07-04 |
Family
ID=79739136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111210020.8A Active CN113980004B (zh) | 2021-10-18 | 2021-10-18 | 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113980004B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000053581A2 (en) * | 1999-03-05 | 2000-09-14 | Novuspharma S.P.A. | Heterocyclic compounds having antitumor activity |
| CN110872264A (zh) * | 2019-12-04 | 2020-03-10 | 河南师范大学 | 含环外z,e-双烯顺式四氢苯并呋喃类化合物及其合成方法 |
| CN111848592A (zh) * | 2019-04-24 | 2020-10-30 | 东莞市东阳光农药研发有限公司 | 4-氨基呋喃-2(5h)酮类化合物、其制备方法及应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6511994B2 (en) * | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
-
2021
- 2021-10-18 CN CN202111210020.8A patent/CN113980004B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000053581A2 (en) * | 1999-03-05 | 2000-09-14 | Novuspharma S.P.A. | Heterocyclic compounds having antitumor activity |
| CN111848592A (zh) * | 2019-04-24 | 2020-10-30 | 东莞市东阳光农药研发有限公司 | 4-氨基呋喃-2(5h)酮类化合物、其制备方法及应用 |
| CN110872264A (zh) * | 2019-12-04 | 2020-03-10 | 河南师范大学 | 含环外z,e-双烯顺式四氢苯并呋喃类化合物及其合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113980004A (zh) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107501160B (zh) | 一种有机催化合成轴手性芳基吲哚的方法 | |
| NL1018776C1 (nl) | Werkwijze voor de bereiding van citalopram. | |
| Kamlar et al. | Formal [3+ 2] cycloaddition of vinylcyclopropane azlactones to enals using synergistic catalysis | |
| JP2010540614A (ja) | モナチン鏡像異性体の生成 | |
| CN108864189A (zh) | 亚磺酰胺类手性单膦配体及其制备方法和应用 | |
| Yakura et al. | Synthesis of an immunomodulator (+)-conagenin and its analogs | |
| TWI397380B (zh) | 含磷之α胺基酸之製造方法及其製造中間體 | |
| CN113980004B (zh) | 一种具有呋喃-2(5h)-酮骨架的化合物及其制备方法 | |
| CN111763197A (zh) | 一种新型手性吲哚类化合物的合成方法 | |
| Yan et al. | One-pot and regioselective synthesis of functionalized γ-lactams via a metal-free sequential Ugi 4CR/intramolecular 5-exo-dig cyclization reaction | |
| CN114044771B (zh) | 具有5-羟基呋喃-2(5h)-酮骨架的化合物及其制备方法 | |
| CN109503387B (zh) | 一种催化不对称合成联萘二胺的方法 | |
| KR20090105309A (ko) | 광학활성을 갖는 5-히드록시-3-옥소헵타노에이트 유도체의제조방법 | |
| CN109608493B (zh) | 一种制备α-氨基磷酸酯类化合物的方法 | |
| CN113087649B (zh) | 一种二氢吡咯酮衍生物的制备方法 | |
| CN108218762B (zh) | 一种2位季碳吲哚-3-酮类化合物的合成方法 | |
| Jiaping et al. | Chiral spirocyclic phosphoric acid-catalyzed enantioselective synthesis of heterotriarylmethanes bearing an amino acid moiety | |
| JP2002540192A (ja) | アザ複素環化合物と二酸化炭素からの複素環カルバマート類の製造方法 | |
| JP2009073739A (ja) | 医薬品中間体として許容しうる高純度な光学活性１−アリール−１，３−プロパンジオールの製造方法 | |
| CN107286203B (zh) | 手性Ugi’s胺和其衍生物及光学异构体的制备方法和应用 | |
| CN113461690B (zh) | 一种手性4,6-二氧八氢吡咯并[3,4-c]吡咯-1-羧酸酯类化合物的合成方法 | |
| KR101201203B1 (ko) | 고순도 메티오졸린의 공업적 제조방법 | |
| JP5458528B2 (ja) | 光学活性ビフェニルリン酸誘導体 | |
| KR101072679B1 (ko) | 아민에 트리플루오로아세틸기 도입시키는 새로운 방법 | |
| JP6498614B2 (ja) | 光学活性カルボン酸エステルの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |